PMID- 36147445
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220924
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - Unicystic Mucoepidermoid Carcinoma: A Pitfall for Clinical and Pathologic 
      Diagnosis.
PG  - 2676367
LID - 10.1155/2022/2676367 [doi]
LID - 2676367
AB  - Unicystic mucoepidermoid carcinoma (UC-MEC) is a rare MEC variant, and its 
      diagnosis is frequently problematic. This study is aimed at summarizing its 
      clinicopathologic characteristics, treatment, and prognosis and proposing key 
      points to avoid missed diagnosis and misdiagnosis in clinical and pathological 
      conditions. This retrospective study included 30 UC-MEC cases, and the clinical 
      findings were collected from the clinical medical records. Radiographic features, 
      histologic behaviors, MAML2 rearrangement by fluorescence in situ hybridization 
      (FISH), and follow-up data were analyzed. Moreover, glandular odontogenic cyst 
      (GOC) and cytadenoma (CA) were used as controls. In the UC-MEC group, 19 patients 
      were female (63%), and 11 were male (37%). The mean patient age was 39.5 (range, 
      7-72 years). The affected locations included the jaw (8 maxillary, 3 mandibular) 
      and salivary glands (7 parotid, 11 palates, and 1 floor of the mouth). The chief 
      complaint was swelling; the lesions were all cystic, among which 66.7% were well 
      circumscribed and 33.3% poorly defined. Microscopic examination showed two UC-MEC 
      histologic subtypes. Type A presented as a single cyst with mural thickening 
      (8/30, 27%) lined predominantly by epidermoid cells with interspersed 
      intermediate and mucinous cells, and type B (22/30, 73%) showed infiltrative 
      tumor islands in the cystic wall or the surrounding tissue. FISH analysis 
      suggested that approximately 66.7% of UC-MEC harbored a MAML2 rearrangement. 
      During the median follow-up period of 42 months (range, 6-120 months), all type A 
      patients and 68% of type B patients who underwent complete surgical resection 
      lived without relapse. Seven cases with type B cancer that underwent curettage 
      initially had local recurrence. Clinicians and pathologists hardly recognize 
      UC-MEC owing to its cystic architecture. Specific epidermoid, mucous, and 
      intermediate tumor cells, and MAML2 fusion testing, are essential to avoid 
      potential diagnostic pitfalls. Prompting and completing resection surgery with 
      negative margins would have a favorable prognosis.
CI  - Copyright (c) 2022 Xi Wang et al.
FAU - Wang, Xi
AU  - Wang X
AD  - Department of Oral Pathology, Peking University School and Hospital of 
      Stomatology & National Center of Stomatology & National Clinical Research Center 
      for Oral Diseases & National Engineering Research Center of Oral Biomaterials and 
      Digital Medical Devices, Beijing 100081, China.
AD  - Research Unit of Precision Pathologic Diagnosis in Tumors of the Oral and 
      Maxillofacial Regions, Chinese Academy of Medical Sciences (2019RU034), China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Oral Pathology, Peking University School and Hospital of 
      Stomatology & National Center of Stomatology & National Clinical Research Center 
      for Oral Diseases & National Engineering Research Center of Oral Biomaterials and 
      Digital Medical Devices, Beijing 100081, China.
AD  - Research Unit of Precision Pathologic Diagnosis in Tumors of the Oral and 
      Maxillofacial Regions, Chinese Academy of Medical Sciences (2019RU034), China.
FAU - Feng, Yanrui
AU  - Feng Y
AD  - Central Laboratory, Peking University School and Hospital of Stomatology & 
      National Center of Stomatology & National Clinical Research Center for Oral 
      Diseases & National Engineering Research Center of Oral Biomaterials and Digital 
      Medical Devices, Beijing 100081, China.
FAU - Liu, Lingchao
AU  - Liu L
AUID- ORCID: 0000-0003-0455-2657
AD  - Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking 
      University Health Science Center, Beijing, China.
FAU - He, Huiying
AU  - He H
AUID- ORCID: 0000-0001-6237-2190
AD  - Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking 
      University Health Science Center, Beijing, China.
FAU - Li, Binbin
AU  - Li B
AUID- ORCID: 0000-0003-0521-2945
AD  - Department of Oral Pathology, Peking University School and Hospital of 
      Stomatology & National Center of Stomatology & National Clinical Research Center 
      for Oral Diseases & National Engineering Research Center of Oral Biomaterials and 
      Digital Medical Devices, Beijing 100081, China.
AD  - Research Unit of Precision Pathologic Diagnosis in Tumors of the Oral and 
      Maxillofacial Regions, Chinese Academy of Medical Sciences (2019RU034), China.
LA  - eng
PT  - Journal Article
DEP - 20220913
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC9489395
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/24 06:01
PMCR- 2022/09/13
CRDT- 2022/09/23 02:39
PHST- 2022/07/08 00:00 [received]
PHST- 2022/08/30 00:00 [accepted]
PHST- 2022/09/23 02:39 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/24 06:01 [medline]
PHST- 2022/09/13 00:00 [pmc-release]
AID - 10.1155/2022/2676367 [doi]
PST - epublish
SO  - J Oncol. 2022 Sep 13;2022:2676367. doi: 10.1155/2022/2676367. eCollection 2022.